ABSTRACT
PURPOSE: Prognosis for adult B-cell acute lymphoblastic leukemia (B-ALL) is poor, and there are currently no licensed CD19 chimeric antigen receptor (CAR) therapeutics. We developed a novel second-generation CD19-CAR (CAT19-41BB-Z) with a fast off rate, designed for more physiologic T-cell activation to reduce toxicity and improve engraftment. We describe the multicenter phase I ALLCAR19 (NCT02935257) study of autologous CAT19-41BB-Z CAR T cells (AUTO1) in relapsed or refractory (r/r) adult B-ALL. METHODS: Patients age ≥ 16 years with r/r B-ALL were eligible. Primary outcomes were toxicity and manufacturing feasibility. Secondary outcomes were depth of response at 1 and 3 months, persistence of CAR-T, incidence and duration of hypogammaglobulinemia and B-cell aplasia, and event-free survival and overall survival at 1 and 2 years. RESULTS: Twenty-five patients were leukapheresed, 24 products were manufactured, and 20 patients were infused with AUTO1. The median age was 41.5 years; 25% had prior blinatumomab, 50% prior inotuzumab ozogamicin, and 65% prior allogeneic stem-cell transplantation. At the time of preconditioning, 45% had ≥ 50% bone marrow blasts. No patients experienced ≥ grade 3 cytokine release syndrome; 3 of 20 (15%) experienced grade 3 neurotoxicity that resolved to ≤ grade 1 within 72 hours with steroids. Seventeen of 20 (85%) achieved minimal residual disease-negative complete response at month 1, and 3 of 17 underwent allogeneic stem-cell transplantation while in remission. The event-free survival at 6 and 12 months was 68.3% (42.4%-84.4%) and 48.3% (23.1%-69.7%), respectively. High-level expansion (Cmax 127,152 copies/µg genomic DNA) and durable CAR-T persistence were observed with B-cell aplasia ongoing in 15 of 20 patients at last follow-up. CONCLUSION: AUTO1 demonstrates a tolerable safety profile, high remission rates, and excellent persistence in r/r adult B-ALL. Preliminary data support further development of AUTO1 as a stand-alone treatment for r/r adult B-ALL.
Subject(s)
Antigens, CD19/immunology , Immunotherapy, Adoptive/adverse effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Receptors, Chimeric Antigen/immunology , T-Lymphocytes/immunology , T-Lymphocytes/transplantation , Adolescent , Adult , Agammaglobulinemia/etiology , B-Lymphocytes/pathology , Bone Marrow/pathology , Cytokine Release Syndrome/etiology , Female , Graft vs Host Disease/etiology , Humans , Infections/etiology , Lymphocyte Count , Male , Middle Aged , Nervous System Diseases/etiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Progression-Free Survival , Recurrence , Retreatment , Survival Rate , Transplantation, Autologous/adverse effects , Treatment Outcome , Young AdultABSTRACT
Enlargement of palatinar tonsils in the course of chronic inflammatory process has been thought till now to reflect pronounced lymphocyte proliferation even if such mechanism fails to explain the persistent increase in size of the organ. The studies were performed on 92 tonsils obtained from 4 to 16 years old children in whom the tonsils were removed due to chronic inflammatory processes in upper respiratory tract or in ears. Cell proliferation and apoptosis were evaluated by flow cytometry and by image analysis. The data show that apoptosis in the tonsils is accompanying lymphocyte proliferation in the course of chronic inflammatory process. Evaluation of homeostasis in palatine tonsils could be helpful in referring children for tonsillectomy. Imagine analysis may objectivize and specify diagnosis of chronic tonsillitis.
